Yan Named Associate Dean of Research and Innovation at Pharmacy College
CINCINNATIBingfang Yan, PhD, has been named associate dean of research and innovation at the University of Cincinnati James L. Winkle College of Pharmacy. In this newly created position, Yan will direct the graduate program, provide leadership on new initiatives, help to increase research productivity and mentor junior faculty in their research.
He also holds the title of professor in the division of pharmaceutical sciences.
"It is critical for us to have a senior leader and mentor at the college to help us to continue to improve our research granting success, which has more than doubled since 2014, says Dean Neil MacKinnon, PhD, noting that college of pharmacy rankings are strongly correlated to research funding. "We are excited to have Dr. Yan on board at the college.
Yan joins the Winkle College of Pharmacy from the University of Rhode Island. His foundation is in veterinary medicine, but he has advanced training in microbiology and immunology, pharmacology/toxicology and tumor biology.
Yans laboratory, which has repeatedly been funded by the NIH, was among the first to clone and characterize the gene encoding the pregnane X receptor (PXR), and the gene encoding differentiated embryo-chondrocyte-expresse gene 1 (DEC1).
PXR is a master regulator for drug-metabolizing enzymes and transporters, whereas DEC1 is a circadian regulator with oncogenic involvement.
Yan frequently serves on scientific review panels at both the NIH and the Environmental Protection Agency (EPA) and is currently a standing member of NIH Study Section INMP.
For additional information about the college, visit the website.
Tags
Related Stories
Cancer Center plays key role in lab research, clinical trials for new pancreatic cancer drug
September 1, 2026
WLWT and WCPO highlighted the contributions of University of Cincinnati Cancer Center researchers that helped lead to the recent FDA approval of daraxonrasib, a new treatment for pancreatic cancer.
Cancer Center physician receives $150,000 New Investigator Research Grant to study treatment-resistant leukemia
September 1, 2026
The University of Cincinnati Cancer Center’s Sarah Skuli, MD, PhD, received a two‑year, $150,000 Leukemia Research Foundation New Investigator Grant to study TP53‑mutated leukemia, a treatment‑resistant subtype with very poor outcomes.
Heavy social media use linked to depression
August 31, 2026
U.S. News and World Report, Yahoo! News, MSN, USA Today and other national media highlight a new study by the University of Cincinnati and Northwestern University that found a correlation between heavy social media use and depression in adults.